版本:
中国

BRIEF-Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

April 25 Epizyme Inc

* Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

* Epizyme Inc - "development goal is to bring tazemetostat to patients as quickly as possible and we look forward to advancing this study throughout 2017" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐